Lupin gets USFDA nod for psoriasis treatment spray
New Delhi: Drug major Lupin today said it has received approval from the US health regulator to market Desoximetasone Topical spray, used for treatment of plaque psoriasis, in the American market.
It is a generic version of Taro Pharmaceuticals USA Inc.'s Topicort Topical Spray, 0.25 per cent.
The approval has been granted to the product in the size of 30 ml, 50 ml, and 100 ml.
In a BSE filing, Lupin said it has received final approval for the spray, 0.25 per cent, from the United States Food and Drug Administration (USFDA).
As per IQVIA MAT data of January 2018, the product had annual sales of around USD 19.5 million in the US.
Read Also: Lupin gets USFDA nod to market antipsychotic drug
It is a generic version of Taro Pharmaceuticals USA Inc.'s Topicort Topical Spray, 0.25 per cent.
The approval has been granted to the product in the size of 30 ml, 50 ml, and 100 ml.
In a BSE filing, Lupin said it has received final approval for the spray, 0.25 per cent, from the United States Food and Drug Administration (USFDA).
As per IQVIA MAT data of January 2018, the product had annual sales of around USD 19.5 million in the US.
Read Also: Lupin gets USFDA nod to market antipsychotic drug
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd